Global Gene Expression Analysis Market Size

Statistics for the 2023 & 2024 Global Gene Expression Analysis market size, created by Mordor Intelligence™ Industry Reports. Global Gene Expression Analysis size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Global Gene Expression Analysis Industry

Gene Expression Analysis Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 8.90 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Gene Expression Analysis Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Gene Expression Analysis Market Analysis

The Gene Expression Analysis Market is projected to register a CAGR of 8.9% during the forecast period.

The COVID-19 pandemic is expected to have a positive effect on the gene expression analysis market. The development of therapeutic and preventive strategies requires an accurate understanding of the role that genomes play in the SARS-CoV-2 infection process and progression of COVID-19. The vast field of genomics is well equipped with the technologies needed to help in facing this challenge. A rise in the analysis of gene expression profiles of SARS-CoV-2 receptors for in silico drug discovery for COVID-19 is a high-impact rendering driver for the segment. For instance, according to an article published in the Antibiotics journal, in March 2022, titled " The Impact of Multiplex PCR in Diagnosing and Managing Bacterial Infections in COVID-19 Patients Self-Medicated with Antibiotics', multiplex polymerase chain reaction (PCR), a powerful and efficient tool, is used to diagnose SARS-CoV-2 infections and that has applications for bacterial identification, as well as determining bacterial resistance to antibiotics. Additionally, a study published in the Frontiers in Genetics publications in May 2022 stated that in COVID-19 patients, the gene profiling and analysis of certain common differentially expressed genes (co-DEGs) could be used for the diagnosis and management of the thrombosis and anticoagulant therapy in the COVID-19 patients. The gene expression analysis of the co-DEGs, along with their biological potential functions, protein-protein interactions, functional enrichment analysis, and study of their molecular mechanisms. Thus, the COVID-19 pandemic is leading to an increased demand for gene expression analysis for detecting coronavirus infection among the population.

Certain factors that are propelling the market growth are increasing government funding regarding genomics, rising technological advancements, and growing adoption of personalized medicine.

Gene expression has emerged as one of the key technologies and is widely used at various stages of the drug development process, such as drug discovery and development procedures, clinical diagnostics, biotechnology, microbiology, and others. The limitations in using existing technologies for disease detection and developing precision medicines have increased the demand for newer technologies which is expected to increase the demand for gene expression analysis, hence propelling the market growth. For instance, the use of microarrays during drug development is constrained by hybridization-based detection and the usage of predesigned oligonucleotide probes. However, the development of Cap Analysis of Gene Expression (CAGE), which enables thorough mapping of the promoters and initiation sites of human transcription, has assisted in overcoming the issue. The method also enables cellular mRNA measurement.

Additionally, with the rise in genetic disorders and increased public awareness of personalized medicine, the need for personalized medicine is expected to develop rapidly over the forecast period. Additionally, the increasing focus of companies in adopting various business strategies such as partnerships, collaborations, and financing to develop precision therapies is promoting the use of personalized medicines among the public and is expected to drive the market. For instance, in May 2022, Illumina entered into a long-term strategic collaboration with Janssen Biotech to accelerate the development of precision medicines. Under this collaboration, the company utilizes Illumina's portfolio of resources, including AI-based genome interpretation tools, whole-genome sequencing, and multi-omic analysis services, for co-developing CDx programs on TruSight Oncology Comprehensive assay, a single test that assesses multiple tumor genes and biomarkers in a patient's cancer.

Furthermore, developing technologically advanced solutions and increasing company activities for developing genomic solutions for various diseases are anticipated to boost market growth over the forecast period. For instance, in July 2022, Epic Bio was launched by the CRISPR Pioneer and received funding of USD 55 million. Epic Bio has developed advanced gene expression systems known as the GEMS (Gene Expression Modulation System) platform, which offers precise modification of gene expression. GEMs consist of the largest library of known novel modulators along with computational genomics capabilities and advanced functions, which are used in the designing of guide RNAs for target genes. Also, in November 2021, Emmes, a Clinical Research Organization (CRO), partnered with MedGenome to accelerate breakthrough treatments powered by human genomics for rare disease patients. This partnership helps in bringing more innovative treatments to patients who are suffering from rare diseases.

However, factors such as lack of skilled labor and the high cost of instruments are likely to restrain the market growth over the forecast period.

Gene Expression Analysis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029)